This research indicates that DMF therapy mitigates cognitive decline, neurodegeneration, and excessive astrocyte activation in the PFC and stratum lacunosum-moleculare caused by TDP-43 overexpression in a mouse model of FTD. The gene discussed is TARDBP; the disease is frontotemporal dementia.